Skip to main content

Table 1 Demographics and baseline clinical characteristics

From: Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study

Demographics
 Sex (male, %)70%
 Age (median, IQR)49.5 (42.8, 59)
 Disease duration (median, IQR)14 (5, 20)
Clinical characteristics
 PASI (median, IQR)6.8 (3.5, 18.6)
 BSA% (median, IQR)10.9 (3.6, 20.3)
 Arthralgia (%)85%
 VAS_pain (median, IQR)18.5 (11.75, 49.5)
 VAS_patient global disease activity (median, IQR)68 (45, 74)
 VAS_physician (median, IQR)35.5 (8.75, 62.75)
 Tender joints (%)40%
 TJC78 (median, IQR; mean ± SD)0 (0, 3.75); 2.65 ± 5.11
 Nail involvement (%)55%
 Scalp involvement (%)75%
  1. Data are based on all 20 psoriasis patients
  2. IQR interquartile range, SD standard deviation, PASI psoriasis area severity index, BSA body surface area, VAS visual analogue scale, TJC tender joint count